HighTower Advisors LLC Cuts Stake in Fresenius Medical Care AG & Co. KGaA $FMS

HighTower Advisors LLC cut its position in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 3.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,358 shares of the company’s stock after selling 532 shares during the period. HighTower Advisors LLC’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $432,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Crossmark Global Holdings Inc. increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 0.9% in the 1st quarter. Crossmark Global Holdings Inc. now owns 64,871 shares of the company’s stock valued at $1,615,000 after purchasing an additional 584 shares during the last quarter. Callan Capital LLC increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 6.6% in the 1st quarter. Callan Capital LLC now owns 13,974 shares of the company’s stock valued at $348,000 after purchasing an additional 870 shares during the last quarter. Wayfinding Financial LLC purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 1st quarter valued at approximately $25,000. Spire Wealth Management purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 1st quarter valued at approximately $27,000. Finally, National Bank of Canada FI increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 4.6% in the 1st quarter. National Bank of Canada FI now owns 31,127 shares of the company’s stock valued at $774,000 after purchasing an additional 1,371 shares during the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on FMS shares. Truist Financial increased their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $25.00 to $30.00 and gave the company a “hold” rating in a research report on Monday, May 12th. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 12th. Zacks Research lowered Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Monday, August 18th. Finally, Wall Street Zen raised Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a report on Friday, August 22nd. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Fresenius Medical Care AG & Co. KGaA presently has an average rating of “Hold” and a consensus price target of $27.80.

Fresenius Medical Care AG & Co. KGaA Stock Performance

NYSE:FMS opened at $25.71 on Monday. Fresenius Medical Care AG & Co. KGaA has a 1-year low of $18.94 and a 1-year high of $30.46. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.44 and a quick ratio of 1.08. The firm has a 50 day simple moving average of $26.23 and a 200-day simple moving average of $25.86.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.50 by $0.02. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. The firm had revenue of $5.54 billion during the quarter, compared to analyst estimates of $5 billion. On average, equities research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.